193 related articles for article (PubMed ID: 10575189)
1. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.
Lhotta K; Kühr T; Rumpelt HJ; Wöll E; Thaler J; König P
Am J Nephrol; 1999; 19(5):590-3. PubMed ID: 10575189
[TBL] [Abstract][Full Text] [Related]
2. Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
Crouzet L; Edeline J; Le Du F; Boucher E; Audrain O; Raoul JL
Acta Oncol; 2012 May; 51(5):687-8. PubMed ID: 22356625
[No Abstract] [Full Text] [Related]
3. Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma.
Nieto-Ríos JF; Zuluaga-Quintero M; Higuita LM; Rincón CI; Galvez-Cárdenas KM; Ocampo-Kohn C; Aristizabal-Alzate A; Florez-Vargas AA; Zuluaga-Valencia GA
J Bras Nefrol; 2016 Jun; 38(2):255-9. PubMed ID: 27438981
[TBL] [Abstract][Full Text] [Related]
4. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.
Saif MW; McGee PJ
JOP; 2005 Jul; 6(4):369-74. PubMed ID: 16006690
[TBL] [Abstract][Full Text] [Related]
5. [Hemolytic-uremic syndrome associated with gemcitabine use: report of one case].
Vega J; Parodi C; Méndez GP; Goecke H
Rev Med Chil; 2013 Jun; 141(6):797-802. PubMed ID: 24121585
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine.
Flombaum CD; Mouradian JA; Casper ES; Erlandson RA; Benedetti F
Am J Kidney Dis; 1999 Mar; 33(3):555-62. PubMed ID: 10070921
[TBL] [Abstract][Full Text] [Related]
7. Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer.
Boeck S; Geiger S; Schulz C; Heinemann V
J Clin Gastroenterol; 2008; 42(5):551-2. PubMed ID: 18344882
[No Abstract] [Full Text] [Related]
8. Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine.
Vénat-Bouvet L; Ly K; Szelag JC; Martin J; Labourey JL; Genet D; Tubiana-Mathieu N
Anticancer Drugs; 2003 Nov; 14(10):829-32. PubMed ID: 14597878
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Held-Warmkessel J
Oncol Nurs Forum; 2014 Sep; 41(5):551-3. PubMed ID: 25158661
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports
.
López Rubio ME; Rodado Martínez R; Illescas ML; Mateo Bosch E; Martinez Díaz M; de la Vara Inesta L; Cabezuelo B; Morales Albuja ME; Lucas Guillén E; Jimeno García L
Clin Nephrol; 2017 Feb; 87 (2017)(2):100-106. PubMed ID: 27879189
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-induced hemolytic uremic syndrome: a case report.
Brodowicz T; Breiteneder S; Wiltschke C; Zielinski CC
J Natl Cancer Inst; 1997 Dec; 89(24):1895-6. PubMed ID: 9414181
[No Abstract] [Full Text] [Related]
12. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.
Lee HW; Chung MJ; Kang H; Choi H; Choi YJ; Lee KJ; Lee SW; Han SH; Kim JS; Song SY
Gut Liver; 2014 Jan; 8(1):109-12. PubMed ID: 24516709
[TBL] [Abstract][Full Text] [Related]
13. [A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
Wato M; Inaba T; Ishikawa H; Ishikawa S; Baba N; Miyoshi M; Senoh T; Nagano T; Takaguchi K; Watanabe S; Kawai K
Nihon Shokakibyo Gakkai Zasshi; 2010 Oct; 107(10):1676-85. PubMed ID: 20938119
[TBL] [Abstract][Full Text] [Related]
14. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
Vogl TJ; Schwarz W; Eichler K; Hochmuth K; Hammerstingl R; Jacob U; Scheller A; Zangos S; Heller M
J Cancer Res Clin Oncol; 2006 Nov; 132(11):745-55. PubMed ID: 16858591
[TBL] [Abstract][Full Text] [Related]
15. [Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].
Dahan L; Ressiot E; Cournede A; Ries P; Duluc M; Laquiere A; Laugier R; Braguer D; Seitz JF
Gastroenterol Clin Biol; 2007 Dec; 31(12):1143-5. PubMed ID: 18176375
[TBL] [Abstract][Full Text] [Related]
16. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
[No Abstract] [Full Text] [Related]
17. [Hemolytic-uremic syndrome complicating a long-term treatment with gemcitabine. Report of a case and review of the literature].
Dilhuydy MS; Delclaux C; Pariente A; De Precigout V; Aparicio M
Rev Med Interne; 2002 Feb; 23(2):189-92. PubMed ID: 11876063
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-associated hemolytic-uremic syndrome.
Walter RB; Joerger M; Pestalozzi BC
Am J Kidney Dis; 2002 Oct; 40(4):E16. PubMed ID: 12324937
[TBL] [Abstract][Full Text] [Related]
19. Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma.
Choi M; Woywodt A; Göbel U; Schneider W; Kettritz R
Nephrol Dial Transplant; 1999 Oct; 14(10):2523-4. PubMed ID: 10528696
[No Abstract] [Full Text] [Related]
20. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.
Bharthuar A; Egloff L; Becker J; George M; Lohr JW; Deeb G; Iyer RV
Cancer Chemother Pharmacol; 2009 Jun; 64(1):177-81. PubMed ID: 19116715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
